ACTINIUM PHARMACEUTICALS, INC. Cash and Restricted Cash
ACTINIUM PHARMACEUTICALS, INC. (ATNM) had Cash and Restricted Cash of $36.81 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-07
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $36.81M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $42.47M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $48.33M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $53.72M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $36.81M 10-Q · filed 2026-08-07 | |
| 2026-03-31 | $42.47M 10-Q · filed 2026-05-08 | |
| 2025-12-31 | $48.33M 10-Q · filed 2026-08-07 | |
| 2025-09-30 | $53.72M 10-Q · filed 2025-11-14 | |
| 2025-06-30 | $60.26M 10-Q · filed 2026-08-07 | |
| 2025-03-31 | $65.65M 10-Q · filed 2026-05-08 | |
| 2024-12-31 | $73.23M 10-Q · filed 2026-08-07 | |
| 2024-09-30 | $78.98M 10-Q · filed 2025-11-14 | |
| 2024-06-30 | $86.36M 10-Q · filed 2025-08-08 | |
| 2024-03-31 | $84.37M 10-Q · filed 2025-05-09 | |
| 2023-12-31 | $76.99M 10-K · filed 2026-03-30 | |
| 2023-09-30 | $83.29M 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $91.58M 10-Q · filed 2024-08-05 | |
| 2023-03-31 | $95.22M 10-Q · filed 2024-04-26 | |
| 2022-12-31 | $109.61M 10-K · filed 2025-03-31 | |
| 2022-09-30 | $112.51M 10-Q · filed 2023-11-02 | |
| 2022-06-30 | $116.72M 10-Q · filed 2023-08-14 | |
| 2022-03-31 | $72.41M 10-Q · filed 2023-05-15 | |
| 2021-12-31 | $78.22M 10-K · filed 2024-03-29 | |
| 2021-09-30 | $82.47M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $82.35M 10-Q · filed 2022-08-12 | |
| 2021-03-31 | $72.69M 10-Q · filed 2022-05-13 | |
| 2020-12-31 | $64.00M 10-K · filed 2023-03-31 | |
| 2020-09-30 | $48.67M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $53.91M 10-Q · filed 2021-07-30 | |
| 2020-03-31 | $6.38M 10-Q · filed 2021-05-14 | |
| 2019-12-31 | $9.69M 10-K · filed 2022-03-25 | $9.69M 10-K · filed 2020-05-08 |
| 2019-09-30 | $14.75M 10-Q · filed 2020-10-23 | $14.75M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $20.00M 10-Q · filed 2020-08-14 | $20.00M 10-Q · filed 2019-08-09 |
| 2019-03-31 | $10.36M 10-Q · filed 2020-06-29 | $10.36M 10-Q · filed 2019-05-10 |
| 2018-12-31 | $14.11M 10-K · filed 2021-03-31 | $14.10M 10-K · filed 2019-03-15 |
| 2018-09-30 | $15.24M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $21.91M 10-Q · filed 2019-08-09 | |
| 2018-03-31 | $27.19M 10-Q · filed 2019-05-10 | |
| 2017-12-31 | $17.79M 10-K · filed 2020-05-08 | |
| 2017-09-30 | $20.93M 10-Q · filed 2018-11-09 | |
| 2017-06-30 | $11.85M 10-Q · filed 2018-08-09 | |
| 2017-03-31 | $17.09M 10-Q · filed 2018-05-10 | |
| 2016-12-31 | $20.55M 10-K · filed 2019-03-15 | |
| 2015-12-31 | $25.68M 10-K · filed 2019-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |